Interventional technology developer C. R. Bard of Murray Hill, NJ, has received U.S. Food and Drug Administration (FDA) clearance to market its E-Luminexx vascular stent.
Designed for the treatment of patients with common or external iliac artery occlusive disease, E-Luminexx is a flexible, self-expanding nitinol stent. It will be marketed by Bard's peripheral vascular division in Tempe, AZ.
Related Reading
Bard boosts sales in Q2, July 24, 2008
Bard posts Q4 results, February 1, 2008
Bard signs Howard, March 13, 2007
Bard closes Venetec deal, April 10, 2006
Bard bids for Venetec, March 2, 2006
Copyright © 2008 AuntMinnie.com